{
    "clinical_study": {
        "@rank": "93951", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (cetuximab and tivantinib)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Arm II (cetuximab)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well cetuximab with or without tivantinib works\n      in treating patients with head and neck cancer that is recurrent, metastatic, or cannot be\n      removed by surgery. Monoclonal antibodies, such as cetuximab, can interfere with tumor\n      growth by blocking the ability of tumor cells to grow and spread. Tivantinib may stop the\n      growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet\n      known whether cetuximab is more effective with or without tivantinib in treating patients\n      with head and neck cancer."
        }, 
        "brief_title": "Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery", 
        "condition": [
            "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", 
            "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", 
            "Recurrent Salivary Gland Cancer", 
            "Recurrent Squamous Cell Carcinoma of the Hypopharynx", 
            "Recurrent Squamous Cell Carcinoma of the Larynx", 
            "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", 
            "Recurrent Squamous Cell Carcinoma of the Nasopharynx", 
            "Recurrent Squamous Cell Carcinoma of the Oropharynx", 
            "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", 
            "Recurrent Verrucous Carcinoma of the Larynx", 
            "Recurrent Verrucous Carcinoma of the Oral Cavity", 
            "Salivary Gland Squamous Cell Carcinoma", 
            "Stage III Salivary Gland Cancer", 
            "Stage III Squamous Cell Carcinoma of the Hypopharynx", 
            "Stage III Squamous Cell Carcinoma of the Larynx", 
            "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", 
            "Stage III Squamous Cell Carcinoma of the Nasopharynx", 
            "Stage III Squamous Cell Carcinoma of the Oropharynx", 
            "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", 
            "Stage III Verrucous Carcinoma of the Larynx", 
            "Stage III Verrucous Carcinoma of the Oral Cavity", 
            "Stage IV Squamous Cell Carcinoma of the Hypopharynx", 
            "Stage IV Squamous Cell Carcinoma of the Nasopharynx", 
            "Stage IVA Salivary Gland Cancer", 
            "Stage IVA Squamous Cell Carcinoma of the Larynx", 
            "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", 
            "Stage IVA Squamous Cell Carcinoma of the Oropharynx", 
            "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", 
            "Stage IVA Verrucous Carcinoma of the Larynx", 
            "Stage IVA Verrucous Carcinoma of the Oral Cavity", 
            "Stage IVB Salivary Gland Cancer", 
            "Stage IVB Squamous Cell Carcinoma of the Larynx", 
            "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", 
            "Stage IVB Squamous Cell Carcinoma of the Oropharynx", 
            "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", 
            "Stage IVB Verrucous Carcinoma of the Larynx", 
            "Stage IVB Verrucous Carcinoma of the Oral Cavity", 
            "Stage IVC Salivary Gland Cancer", 
            "Stage IVC Squamous Cell Carcinoma of the Larynx", 
            "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", 
            "Stage IVC Squamous Cell Carcinoma of the Oropharynx", 
            "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", 
            "Stage IVC Verrucous Carcinoma of the Larynx", 
            "Stage IVC Verrucous Carcinoma of the Oral Cavity", 
            "Tongue Cancer", 
            "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms", 
                "Laryngeal Diseases", 
                "Tongue Neoplasms", 
                "Carcinoma, Verrucous", 
                "Neoplasms, Unknown Primary", 
                "Salivary Gland Neoplasms", 
                "Hypopharyngeal Neoplasms", 
                "Laryngeal Neoplasms", 
                "Paranasal Sinus Neoplasms", 
                "Oropharyngeal Neoplasms", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Response rate. We will compare the cetuximab/ARQ 197 (tivantinib) combination with\n      cetuximab single agent activity.\n\n      SECONDARY OBJECTIVES:\n\n      I. Continuous tumor shrinkage. II. Progression-free survival (PFS). III. Overall survival\n      (OS). IV. Endpoints I), II), and III) above, as well as response rates, will be assessed and\n      compared between treatment arms in the subgroup of patients with high mesenchymal epithelial\n      transition factor (c-MET) expression, and/or high c-MET copy number.\n\n      V. Single agent activity for ARQ 197 (tivantinib) in patients who have failed cetuximab.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1 and 15\n      and tivantinib orally (PO) twice daily (BID) on days 1-28.\n\n      ARM II: Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who\n      fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28.\n\n      In both arms, courses repeat every 4 weeks in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically/cytologically confirmed diagnosis of squamous cell carcinoma of head\n             and neck origin not amenable to curative intent therapy; both human papillomavirus\n             (HPV) positive (+) and HPV negative (-) are eligible, but status has to be known\n             prior to randomization (although not required for consenting); any type of tissue\n             based HPV assessment is acceptable (e.g. p16 immunohistochemistry [IHC] or HPV in\n             situ hybridization [ISH]); if local HPV testing is not available slides can be sent\n             to the University of Chicago for HPV testing; please note that p16 IHC is generally\n             only considered to be accurate for oropharyngeal tumors\n\n          -  Presence of measurable lesions (as per Response Evaluation Criteria in Solid Tumors\n             [RECIST]1.1); generally a >= 10 mm tumor lesion (in the longest diameter by computed\n             tomography [CT] scan) or a lymph node >= 15 mm (short axis) is considered measurable\n             disease when evaluated by CT scan (with a slice thickness no greater than 5 mm)\n\n          -  Availability of tissue (10 tumor containing formalin-fixed, paraffin-embedded [FFPE]\n             slides/sections)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1\n\n          -  Patients who have received cetuximab or another inhibitor of epidermal growth factor\n             receptor (EGFR) in the curative intent treatment setting (e.g. with radiation or\n             during induction chemotherapy [prior to definitive, curative intent therapy]) are\n             eligible for the study\n\n          -  Life expectancy of greater than 8 weeks\n\n          -  Hemoglobin >= 9.0 g/dL\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin =< 1.5 X institutional upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 X institutional upper limit of normal\n\n          -  Serum creatinine =< 1.5 X institutional upper limit of normal OR creatinine clearance\n             >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\n\n          -  Patients must be able to swallow ARQ 197 (tivantinib) by mouth, unless adequate data\n             about administration by gastrostomy (G)-tube becomes available; tablets may be\n             crushed, but must be taken orally\n\n          -  Human immunodeficiency virus (HIV)-positive patients with normal immune function\n             (cluster of differentiation [CD]4 count > 200) are eligible if there are no drug\n             interactions with ARQ 197 (tivantinib) or cetuximab\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and\n             for the duration of study participation; should a woman become pregnant or suspect\n             she is pregnant while she or her partner is participating in this study, she should\n             inform her treating physician immediately; men treated or enrolled on this protocol\n             must also agree to use adequate contraception prior to the study, for the duration of\n             study participation, and 4 months after completion of ARQ 197 (tivantinib)\n             administration\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n             recovered from adverse events due to agents administered more than 2 weeks earlier\n\n          -  Nasopharyngeal tumors that show lymphoepithelioma histology\n\n          -  Patients who have received more than 2 prior cytotoxic treatments in the palliative\n             treatment setting are ineligible\n\n          -  Patients who have received treatment with an EGFR or MET inhibitor in the palliative\n             treatment setting are ineligible\n\n          -  Patients with known, active brain metastases should be excluded from this clinical\n             trial; patients with treated brain metastases stable for >= 12 weeks are eligible;\n             use of corticosteroid (for patients with brain metastasis and other indications for\n             corticosteroid use) is acceptable on a low maintenance or tapering dose schedule\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to ARQ 197 (tivantinib) or cetuximab\n\n          -  Concurrent life-threatening diseases: patients with diseases which with reasonable\n             certainty do not limit life expectancy to 12 months or less are eligible; assessment\n             of such concurrent illnesses should be by the principal investigator\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with ARQ 197 (tivantinib)\n\n          -  Concurrent use of warfarin (therapeutic use) is allowed, but requires close\n             monitoring of prothrombin time (PT)/international normalized ratio (INR)\n\n          -  History of congestive heart failure defined as class II to IV per New York Heart\n             Association (NYHA) classification; active coronary artery disease (CAD), clinically\n             significant bradycardia or other uncontrolled, cardiac arrhythmia defined as >= grade\n             3 according to National Cancer Institute (NCI) Common Terminology Criteria for\n             Adverse Events (CTCAE), version 4.0, or uncontrolled hypertension; myocardial\n             infarction occurring within 6 months prior to study entry (myocardial infarction\n             occurring > 6 months prior to study entry is permitted)\n\n          -  Patients may not be receiving any other investigational agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696955", 
            "org_study_id": "NCI-2012-01640", 
            "secondary_id": [
                "NCI-2012-01640", 
                "478834", 
                "12-1359", 
                "9165", 
                "N01CM00099", 
                "P30CA014599", 
                "N01CM00038", 
                "N01CM00071"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (cetuximab and tivantinib)", 
                "description": "Given PO", 
                "intervention_name": "tivantinib", 
                "intervention_type": "Drug", 
                "other_name": "ARQ 197"
            }, 
            {
                "arm_group_label": [
                    "Arm I (cetuximab and tivantinib)", 
                    "Arm II (cetuximab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "cetuximab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "C225", 
                    "C225 monoclonal antibody", 
                    "IMC-C225", 
                    "MOAB C225", 
                    "monoclonal antibody C225"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (cetuximab and tivantinib)", 
                    "Arm II (cetuximab)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Curtis.kelly1@mayo.edu", 
                    "last_name": "Kelly K. Curtis", 
                    "phone": "480-301-8296"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Mayo Clinic in Arizona"
                }, 
                "investigator": {
                    "last_name": "Kelly K. Curtis", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Dlim@coh.org", 
                    "last_name": "Dean W. Lim", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Dean W. Lim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gitlitz@usc.edu", 
                    "last_name": "Barbara J. Gitlitz", 
                    "phone": "323-865-3959"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Barbara J. Gitlitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Skoehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91105"
                    }, 
                    "name": "City of Hope Medical Group Inc"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "david.gandara@ucdmc.ucdavis.edu", 
                    "last_name": "David R. Gandara", 
                    "phone": "916-734-3771"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David R. Gandara", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Skoehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "South Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91030"
                    }, 
                    "name": "City of Hope South Pasadena"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tseiwert@medicine.bsd.uchicago.edu", 
                    "last_name": "Tanguy Y. Seiwert", 
                    "phone": "773-702-2452"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Tanguy Y. Seiwert", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "m-agulnik@northwestern.edu", 
                    "last_name": "Mark Agulnik", 
                    "phone": "312-695-0990"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Mark Agulnik", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "JLWADE3@sbcglobal.net", 
                    "last_name": "James L. Wade", 
                    "phone": "217-876-6600"
                }, 
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62526"
                    }, 
                    "name": "Decatur Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "James L. Wade", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bbrockstein@northshore.org", 
                    "last_name": "Bruce E. Brockstein", 
                    "phone": "847-570-2515"
                }, 
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60201"
                    }, 
                    "name": "NorthShore University HealthSystem-Evanston Hospital"
                }, 
                "investigator": {
                    "last_name": "Bruce E. Brockstein", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mfkozloff@aol.com", 
                    "last_name": "Mark F. Kozloff", 
                    "phone": "708-339-4800"
                }, 
                "facility": {
                    "address": {
                        "city": "Harvey", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60426"
                    }, 
                    "name": "Ingalls Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Mark F. Kozloff", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sthomas@illinoiscancercare.com", 
                    "last_name": "Sachdev P. Thomas", 
                    "phone": "309-243-3605"
                }, 
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61615"
                    }, 
                    "name": "Illinois CancerCare-Peoria"
                }, 
                "investigator": {
                    "last_name": "Sachdev P. Thomas", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "krao@siumed.edu", 
                    "last_name": "Krishna A. Rao", 
                    "phone": "217-545-7969"
                }, 
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62702"
                    }, 
                    "name": "Southern Illinois University School of Medicine - Department of Surgery"
                }, 
                "investigator": {
                    "last_name": "Krishna A. Rao", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ledgar@fwmoh.com", 
                    "last_name": "Sreenivasa R. Nattam", 
                    "phone": "260-484-8830"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Wayne", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46845"
                    }, 
                    "name": "Fort Wayne Medical Oncology and Hematology Inc-Parkview"
                }, 
                "investigator": {
                    "last_name": "Sreenivasa R. Nattam", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wagnerst@iupui.edu", 
                    "last_name": "Stephanie A. Wagner", 
                    "phone": "317-962-9000"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Stephanie A. Wagner", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mohammed-milhem@uiowa.edu", 
                    "last_name": "Mohammed M. Milhem", 
                    "phone": "319-356-2324"
                }, 
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University of Iowa Hospitals and Clinics"
                }, 
                "investigator": {
                    "last_name": "Mohammed M. Milhem", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dzandberg@umm.edu", 
                    "last_name": "Dan P. Zandberg", 
                    "phone": "410-328-7904"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland/Greenebaum Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Dan P. Zandberg", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fworden@umich.edu", 
                    "last_name": "Francis P. Worden", 
                    "phone": "734-936-0453"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan University Hospital"
                }, 
                "investigator": {
                    "last_name": "Francis P. Worden", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sukaria@karmanos.org", 
                    "last_name": "Ammar Sukari", 
                    "phone": "313-576-8778"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University/Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Ammar Sukari", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "price.katherine@mayo.edu", 
                    "last_name": "Katharine A. Price", 
                    "phone": "507-284-2511"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Katharine A. Price", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Daniel.m.anderson@healthpartners.com", 
                    "last_name": "Daniel M. Anderson", 
                    "phone": "952-993-1517"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis Park", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55416"
                    }, 
                    "name": "Metro-Minnesota CCOP"
                }, 
                "investigator": {
                    "last_name": "Daniel M. Anderson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "slecbg@stlo.mercy.net", 
                    "last_name": "Bethany G. Sleckman", 
                    "phone": "314-251-7057"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "Saint John's Mercy Medical Center"
                }, 
                "investigator": {
                    "last_name": "Bethany G. Sleckman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dadkins@dom.wustl.edu", 
                    "last_name": "Douglas R. Adkins", 
                    "phone": "314-362-5654"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Douglas R. Adkins", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cbelani@psu.edu", 
                    "last_name": "Chandra P. Belani", 
                    "phone": "717-531-1078"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033-0850"
                    }, 
                    "name": "Penn State Milton S Hershey Medical Center"
                }, 
                "investigator": {
                    "last_name": "Chandra P. Belani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "baumanje@upmc.edu", 
                    "last_name": "Julie E. Bauman", 
                    "phone": "412-648-6589"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "UPMC Hillman Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Julie E. Bauman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer", 
        "overall_official": {
            "affiliation": "University of Chicago Phase 2 Consortium", 
            "last_name": "Tanguy Seiwert", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response rates in the two arms will be compared using a continuity-corrected chi square test. A sample size of n=38 patients per arm will provide 80% power to detect a difference of 12% vs 35% between the cetuximab and combination treatment arms, using a one-sided test at the alpha = 0.10 significance level.", 
            "measure": "Response rate assessed according to RECIST", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "removed_countries": {
            "country": "China"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696955"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Early change in tumor burden will be compared between groups using two-sample t-tests. Waterfall plots will be constructed for graphical comparison.", 
                "measure": "Change in tumor burden, measured using the sum of longest diameters of target lesion", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 8 weeks"
            }, 
            {
                "description": "Kaplan-Meier curves will be generated for PFS and the treatment arms compared via log rank tests.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "From start of treatment to time of progression or death of any cause, assessed up to 5 years"
            }, 
            {
                "description": "Kaplan-Meier curves will be generated for OS and the treatment arms compared via log rank tests.", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number. Logistic and Cox proportional hazards regression models to examine the change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number.", 
                "measure": "Change in c-MET expression", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 8 weeks"
            }, 
            {
                "description": "Change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number. Logistic and Cox proportional hazards regression models to examine the change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number.", 
                "measure": "Change in c-MET copy number", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 8 weeks"
            }, 
            {
                "measure": "Activity of single-agent tivantinib after failure of cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}